Repair & Recovery: A Research Literature Overview

NOVA Q Research · Research Library

Repair & Recovery: A Research Literature Overview

What the published research examines across BPC-157, TB-500 (thymosin β4), KPV, and ARA-290 (cibinetide) — and how mature that evidence actually is.

Neutral literature aggregation · Compiled by NOVA Q Research · Updated 2026-07-24 · 15 cited sources
In brief
  • BPC-157 research is essentially all preclinical (rodent and in-vitro injury models), much of it from a small number of affiliated groups.
  • “TB-500” refers to a fragment of thymosin β4; most primary evidence concerns the full-length parent molecule, largely in animal and ophthalmic models.
  • KPV, a fragment of α-MSH, is studied mainly in cell and rodent models of intestinal inflammation.
  • ARA-290 (cibinetide) is the most clinically developed of the four, with randomized placebo-controlled trials in sarcoidosis-associated small-fiber neuropathy.

Tissue-repair research examines overlapping biological processes: inflammation resolution, angiogenesis, extracellular-matrix remodeling, cell migration, and re-epithelialization. The four compounds below are commonly grouped under a “repair and recovery” heading, but they differ sharply in how developed their evidence is. Two (BPC-157 and the TB-500 fragment) rest largely on preclinical work; one (KPV) is studied mostly in cell and rodent inflammation models; and one (ARA-290) has multiple published randomized human trials in a narrow indication. Reading them side by side is the clearest way to see where the science stands.

BPC-157

Class / mechanism. A synthetic stable pentadecapeptide (15 amino acids) with a sequence derived from a protein fragment identified in gastric juice. Reported mechanistic research examines angiogenic signaling (e.g. VEGFR2/eNOS), nitric-oxide-system interactions, and growth-factor/focal-adhesion signaling.

The published BPC-157 record is almost entirely preclinical, comprising rodent injury models and in-vitro cell-culture experiments. Investigations span tendon, muscle, ligament, bone, gastrointestinal, and vascular injury paradigms, and the group most associated with the compound has produced the majority of studies.

There are no adequately powered randomized controlled human efficacy trials in the literature, and the compound is not an approved drug. Findings are best read as hypothesis-generating.

Selected literature

  1. Chang CH, et al. 2011. “The promoting effect of pentadecapeptide BPC 157 on tendon healing.” J Appl Physiol 110(3):774–780. PMID 21030672. https://pubmed.ncbi.nlm.nih.gov/21030672/In-vitro study of tendon-fibroblast outgrowth, survival, and migration.
  2. Krivic A, et al. 2006. “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157.” J Orthop Res 24(5):982–989. PMID 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/Tendon-to-bone healing measures in a rat detachment model.
  3. Sikiric P, et al. 2018. “Stable gastric pentadecapeptide BPC 157: vascular recruitment and gastrointestinal tract healing.” Curr Pharm Des 24(18). PMID 29879879. https://pubmed.ncbi.nlm.nih.gov/29879879/Narrative review of proposed vascular/cytoprotective mechanisms in preclinical models.
  4. Seiwerth S, et al. 2021. “Stable gastric pentadecapeptide BPC 157 and wound healing.” Front Pharmacol 12:627533. https://www.frontiersin.org/articles/10.3389/fphar.2021.627533/fullReview compiling reported preclinical wound-healing findings.
Where the evidence is limited. Evidence is preclinical, and a large share originates from a small number of affiliated research groups, so independent replication is limited. No published human randomized controlled trials establish efficacy or safety.

TB-500 (thymosin β4 fragment)

Class / mechanism. “TB-500” is the research-market label for a synthetic peptide corresponding to, or derived from, the actin-binding region of thymosin β4, a naturally occurring 43-amino-acid actin-sequestering peptide. Studied mechanisms include actin regulation, cell migration, and angiogenesis.

Most primary literature concerns full-length thymosin β4 rather than the abbreviated “TB-500” product specifically. Thymosin β4 has a substantial preclinical base across dermal, corneal, and cardiac injury models, plus some early-stage clinical development in narrow indications such as ophthalmic surface disease.

Evidence directly characterizing marketed “TB-500” fragments is thinner than for the parent molecule, a distinction worth keeping in view when reading this area.

Selected literature

  1. Malinda KM, et al. 1999. “Thymosin β4 accelerates wound healing.” J Invest Dermatol 113(3):364–368. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/Re-epithelialization and cell-migration endpoints in a rodent dermal-wound model.
  2. Smart N, et al. 2007. “Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization.” Nature 445(7124):177–182. https://www.nature.com/articles/nature05383Epicardial progenitor mobilization and vessel formation in a mouse cardiac model.
  3. Sosne G, et al. 2007. “Thymosin β4 and the eye: modes of action and therapeutic potential.” Ann N Y Acad Sci 1112. https://nyaspubs.onlinelibrary.wiley.com/doi/10.1196/annals.1415.004Review of corneal wound-healing and anti-inflammatory endpoints in ocular models.
  4. Goldstein AL, et al. 2015. “Advances in the basic and clinical applications of thymosin β4.” Expert Opin Biol Ther 15(Suppl 1). https://www.tandfonline.com/doi/abs/10.1517/14712598.2015.1011617Review surveying reported preclinical and early clinical applications.
Where the evidence is limited. Most primary evidence involves full-length thymosin β4 in animal or cell models rather than the marketed fragment, and robust large-scale human efficacy trials outside limited ophthalmic development are lacking.

KPV

Class / mechanism. A tripeptide (lysine-proline-valine) corresponding to the C-terminal (11–13) sequence of α-melanocyte-stimulating hormone (α-MSH). Studied mechanisms include down-modulation of pro-inflammatory NF-κB signaling and cellular uptake via the peptide transporter PepT1.

The KPV literature is predominantly preclinical: in-vitro epithelial and immune-cell assays and rodent colitis models, often framed within the broader melanocortin anti-inflammatory field. A notable strand investigates targeted oral-delivery nanoparticle systems for intestinal inflammation.

Published human randomized controlled trials specific to KPV are not established in the accessible literature.

Selected literature

  1. Dalmasso G, et al. 2008. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology 134(1):166–178. PMID 18061177. https://pubmed.ncbi.nlm.nih.gov/18061177/PepT1-dependent uptake and effects on colitis measures in cell and mouse models.
  2. Kannengiesser K, et al. 2008. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of IBD.” Inflamm Bowel Dis 14(3):324–331. PMID 18092346. https://pubmed.ncbi.nlm.nih.gov/18092346/Inflammatory endpoints in two mouse colitis models.
  3. Xiao B, et al. 2017. “Orally targeted delivery of tripeptide KPV via hyaluronic-acid-functionalized nanoparticles.” Mol Ther 25(7). https://www.sciencedirect.com/science/article/pii/S1525001616454316Nanoparticle oral-delivery system and colonic inflammation in a mouse model.
Where the evidence is limited. Evidence is largely in-vitro and rodent-based and concentrated in gastrointestinal-inflammation models; there is a lack of published human clinical efficacy trials.

ARA-290 (cibinetide)

Class / mechanism. An 11-amino-acid synthetic peptide derived from a region of erythropoietin (EPO), engineered to be non-erythropoietic. Described as an agonist of the proposed “innate repair receptor,” studied for tissue-protective signaling without EPO’s red-blood-cell effects.

Among the four compounds, ARA-290 has the most developed clinical evidence: published randomized, double-blind, placebo-controlled trials in sarcoidosis-associated small-fiber neuropathy, alongside foundational preclinical work. Reported human endpoints include neuropathic-pain scores and corneal nerve-fiber density measured by confocal microscopy.

It has been evaluated as an investigational agent and is not an approved drug.

Selected literature

  1. Brines M, et al. 2008. “Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.” PNAS 105(31):10925–10930. https://www.pnas.org/doi/10.1073/pnas.0805594105Design of EPO-derived non-erythropoietic peptides; tissue-protection endpoints in preclinical models.
  2. Heij L, et al. 2012. “Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small-fiber neuropathy.” Mol Med 18:1430–1436. PMID 23168581. https://pubmed.ncbi.nlm.nih.gov/23168581/Randomized double-blind placebo-controlled pilot; safety and neuropathic-symptom scores.
  3. Culver DA, et al. 2017. “Cibinetide improves corneal nerve fiber abundance in sarcoidosis-associated small-fiber loss.” Invest Ophthalmol Vis Sci 58(6):BIO52–BIO60. https://iovs.arvojournals.org/article.aspx?articleid=2625918Randomized trial evaluating corneal nerve-fiber measures and pain endpoints.
  4. Dahan A, et al. 2013. “ARA 290 improves symptoms in sarcoidosis-associated small nerve fiber loss.” Mol Med 19:334–345. https://pubmed.ncbi.nlm.nih.gov/24071921/Symptom scores and corneal nerve-fiber density as an objective measure.
Where the evidence is limited. Published human trials are concentrated in small sarcoidosis-associated small-fiber-neuropathy populations with modest sample sizes; larger confirmatory and broader-indication data remain limited.

How to read this report

This report aggregates published scientific literature for the compounds NOVA Q Research supplies in the Repair & Recovery category. It describes what studies investigated, the models used, and the maturity of the evidence. It does not evaluate, recommend, or imply any use in humans or animals, and it is not medical, veterinary, or research-protocol advice. Where the record is preclinical or geographically concentrated, we say so. Every source is cited so it can be checked independently.

Browse the Repair & Recovery catalog →
For research use only. Not for human or veterinary use. NOVA Q Research supplies research-grade materials for laboratory research use only. Nothing in this document is intended to diagnose, treat, cure, or prevent any disease, or to guide human or veterinary use. Statements have not been evaluated by the FDA. Citations are provided for reference and do not imply endorsement.